Table 1.
Representative EGFR TKIs currently in use or development
First generation (target WT EGFR) | Second generation (irreversible inhibitors of EGFR and HER2) | Third generation (EGFR mutant-specific, irreversible inhibitors) |
---|---|---|
| ||
Erlotinib* | Neratinib | Rociletinib (Clovis) |
Gefitinib | Afatinib* | AZD9291 (AstraZeneca) |
Icotinib | Dacomitinib | HM61713 (Hanmi) EGF816 (Novartis) ASP8273 (Astellas) |
FDA-approved in the US for treatment of lung cancer